ArticleAmerican journal of cancer research2026
Construction and external validation of a prognostic model for high-grade glioma based on IDH1 mutation status: implications for concurrent chemoradiotherapy efficacy.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective cohort study investigated the impact of isocitrate dehydrogenase 1 (IDH1) mutations on the efficacy and prognosis of concurrent chemoradiotherapy in high-grade gliomas (HGGs) and constructed a validated overall survival (OS) nomogram model. A total of 242 patients were included in the training cohort (2019-2021) and 182 patients in the time validation cohort (2022-2023). All patients received standard concurrent chemoradiotherapy. The median progression-free survival (PFS) in the 72 IDH1-mutant patients was 27.0 months, significantly longer than the 12.0 months in the 170 wild-type patients (hazard ratio =1.79; P<0.001). OS was also longer in IDH1-mutant patients (this endpoint has not yet been met), while the OS in wild-type patients was 20.0 months (HR=2.55; P<0.001). Furthermore, the objective response rate (ORR) in IDH1-mutant patients was 58.3%, significantly higher than the 37.6% in wildtype patients (P=0.005); the disease control rate was 88.9%, also higher than the 76.5% in wildtype patients (P=0.041). Cox regression analysis identified five independent prognostic factors associated with OS: IDH1 wildtype (HR=1.638), Karnofsky Performance Status (KPS) score <70 (HR=1.396), WHO grade 4 (HR=2.273), O
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.